OptimizeRx’s (OPRX) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities reiterated their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $8.00 price objective on the stock.

Several other analysts have also weighed in on the stock. Barclays dropped their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th. B. Riley lowered their price target on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, December 24th. Stifel Nicolaus dropped their price objective on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $16.00 price target (down previously from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Stock Down 2.8 %

NASDAQ OPRX opened at $5.51 on Thursday. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65. The stock’s 50 day moving average is $5.24 and its two-hundred day moving average is $6.58. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Activity

In other news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of OptimizeRx

Several institutional investors and hedge funds have recently bought and sold shares of OPRX. SBI Securities Co. Ltd. acquired a new position in OptimizeRx in the 4th quarter valued at about $25,000. AMH Equity Ltd increased its holdings in OptimizeRx by 25.0% in the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company’s stock valued at $608,000 after buying an additional 25,000 shares during the period. Greenwood Capital Associates LLC raised its position in OptimizeRx by 31.5% during the fourth quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company’s stock valued at $431,000 after purchasing an additional 21,240 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of OptimizeRx during the 4th quarter worth $51,000. Finally, Barclays PLC lifted its position in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after buying an additional 21,060 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.